Pacific Therapeutics (PCFTF) 0.0249 $PCFTF
Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pacific Therapeutics Ltd. Announces Change Of Auditor
ACCESSWIRE - Wed Apr 22, 7:17PM CDT
VANCOUVER, BC / ACCESSWIRE / April 22, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (Frankfurt: 1P3) (the "Company" announces that, effective April 22, 2015 it has changed auditors. on April 16, 2015 the Company announced the resignation of James Stafford Inc. Chartered Accountants as its auditor.
PT: 0.66 (-0.03)
Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
ACCESSWIRE - Fri Apr 10, 7:41AM CDT
VANCOUVER, BC / ACCESSWIRE / April 10, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (OTC
CFTF) (1P3.F) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing approved drugs for large markets.
PT: 0.66 (-0.03)
Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pacific Therapeutics Announces Non-Brokered Financing
ACCESSWIRE - Mon Feb 16, 1:12PM CST
VANCOUVER, BC / ACCESSWIRE / February 16, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 395.42 (+4.18), PSTI: 2.72 (+0.04), ASPX: 100.96 (unch), LPTN: 1.75 (-0.08), IBIO: 0.92 (+0.03), FGEN: 19.90 (-0.48), AQXP: 7.44 (+0.10), GALT: 2.83 (+0.07), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), GILD: 111.00 (+1.70), CGEN: 6.58 (+0.13), FPRX: 21.32 (+0.21), CELGZ: 2.60 (unch)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.90 (unch), APRI: 1.34 (-0.04)
Pacific Therapeutics CEO Provides Corporate Update To Shareholders
ACCESSWIRE - Thu Jan 08, 7:32AM CST
VANCOUVER, BC / ACCESSWIRE / January 8, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (1P3.F) (the "Company" ("Pacific" is a clinical stage Specialty Pharmaceutical Company using proprietary technologies to repurpose and reformulate FDA approved drugs to address large market opportunities as well as increase efficacy and patient compliance. Pacific Therapeutics has licensed a technology for an approved drug to treat erectile dysfunction, reformulated using a fast acting oral disintegrating tablet (ODT) preferred by consumers. In addition, with its partner IntelGenx Corp (IGXT), Pacific is combining two approved drugs into a once-a-day tablet to treat diseases of excessive scarring such as pulmonary fibrosis.
Pacific Therapeutics Secures DTC Eligibility
ACCESSWIRE - Tue Jan 06, 7:32AM CST
VANCOUVER, BC / ACCESSWIRE / January 6, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (1P3.F) (the "Company" has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial.
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 395.42 (+4.18), GILD: 111.00 (+1.70), CGEN: 6.58 (+0.13), ASPX: 100.96 (unch), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36)
Pacific Therapeutics Announces First Nine Months 2014 Financial Results
ACCESSWIRE - Tue Dec 02, 3:54PM CST
VANCOUVER, BC / ACCESSWIRE / December 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (1P3.F) (the "Company" has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial.
Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pacific Therapeutics Ltd. Announces Change Of Auditor
ACCESSWIRE - Wed Apr 22, 7:17PM CDT
VANCOUVER, BC / ACCESSWIRE / April 22, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (Frankfurt: 1P3) (the "Company"
announces that, effective April 22, 2015 it has changed auditors. on April 16, 2015 the Company announced the resignation of James Stafford Inc. Chartered Accountants as its auditor. PT: 0.66 (-0.03)
Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
ACCESSWIRE - Fri Apr 10, 7:41AM CDT
VANCOUVER, BC / ACCESSWIRE / April 10, 2015 / Pacific Therapeutics Ltd. (CNSX: PT) (OTC
CFTF) (1P3.F) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing approved drugs for large markets. PT: 0.66 (-0.03)
Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pacific Therapeutics Announces Non-Brokered Financing
ACCESSWIRE - Mon Feb 16, 1:12PM CST
VANCOUVER, BC / ACCESSWIRE / February 16, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 395.42 (+4.18), PSTI: 2.72 (+0.04), ASPX: 100.96 (unch), LPTN: 1.75 (-0.08), IBIO: 0.92 (+0.03), FGEN: 19.90 (-0.48), AQXP: 7.44 (+0.10), GALT: 2.83 (+0.07), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), GILD: 111.00 (+1.70), CGEN: 6.58 (+0.13), FPRX: 21.32 (+0.21), CELGZ: 2.60 (unch)
Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.90 (unch), APRI: 1.34 (-0.04)
Pacific Therapeutics CEO Provides Corporate Update To Shareholders
ACCESSWIRE - Thu Jan 08, 7:32AM CST
VANCOUVER, BC / ACCESSWIRE / January 8, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (1P3.F) (the "Company"
("Pacific" is a clinical stage Specialty Pharmaceutical Company using proprietary technologies to repurpose and reformulate FDA approved drugs to address large market opportunities as well as increase efficacy and patient compliance. Pacific Therapeutics has licensed a technology for an approved drug to treat erectile dysfunction, reformulated using a fast acting oral disintegrating tablet (ODT) preferred by consumers. In addition, with its partner IntelGenx Corp (IGXT), Pacific is combining two approved drugs into a once-a-day tablet to treat diseases of excessive scarring such as pulmonary fibrosis. Pacific Therapeutics Secures DTC Eligibility
ACCESSWIRE - Tue Jan 06, 7:32AM CST
VANCOUVER, BC / ACCESSWIRE / January 6, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (1P3.F) (the "Company"
has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial. Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 395.42 (+4.18), GILD: 111.00 (+1.70), CGEN: 6.58 (+0.13), ASPX: 100.96 (unch), GSK: 44.66 (-0.11), BMY: 68.00 (+0.36)
Pacific Therapeutics Announces First Nine Months 2014 Financial Results
ACCESSWIRE - Tue Dec 02, 3:54PM CST
VANCOUVER, BC / ACCESSWIRE / December 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (1P3.F) (the "Company"
has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive results and is advancing its sublingual formulation for erectile dysfunction (ED) to a pivotal bioequivalence trial. 
